Gain Access to exclusive preclinical content.
Complete the form below to gain access to mattis aliquet nunc aliquam tempor. We’ll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
I plan to study GFR in obese vs. lean animals. FITC-Sinistrin is measured transdermally. Do I need to take the increased body mass into account?

We are aware of the ongoing discussions of GFR normalization to body weight. Our system detects the decrease of fluorescence of FITC-Sinistrin in the extracellular space. Thus, increased fat content does not influence the measurement (no lipid binding has been reported for FITC-Sinistrin). Many researchers have used our tGFR System in obese animals (please see the list of publications on our website).

Regarding normalization to bodyweight it has been reported that GFR/bodyweight declines after a certain bodyweight. However, this is due to the normalization itself rather than to an actual decline in function. Also, this decline is seen in GFR regardless of the technique you choose for GFR measurement.1 Therefore, our advice is to evaluate both normalized as well as absolute GFR independently in your publication/research.

  1. Provoost AP, de Keijzer MH, Wolff ED, et al. Development of renal function in the rat. The measurement of GFR and ERPF and correlation to body and kidney weight. Ren Physiol 1983; 6: 1-9.